<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>34(9)</volume><submitter>Min KH</submitter><funding>National Research Foundation of Korea</funding><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Anticoagulation therapy is required to prevent thromboembolic complications in patients with heart valve surgery (HVS). However, caution must be taken due to the risk of bleeding. This study aimed to identify bleeding risk factors in patients with stable warfarin therapy and develop a predictive tool for high-risk patients.&lt;h4>Methods&lt;/h4>This study is a nested case-control design using the Korean National Health Insurance Service-National Sample Cohort Data. We identified patients who underwent HVS and were prescribed warfarin within 1 week after the procedure. Of these, patients with the last two identical warfarin prescriptions within 6 months before the bleeding events were defined as the case group, while patients with no bleeding events within 6 months after HVS and t</pubmed_abstract><journal>Pharmacoepidemiology and drug safety</journal><pagination>e70209</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12437997</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>One-Year Risk of Bleeding in Patients on a Stable Warfarin Dose After Prosthetic Heart Valve Surgery.</pubmed_title><pmcid>PMC12437997</pmcid><pubmed_authors>Lee KE</pubmed_authors><pubmed_authors>Min KH</pubmed_authors><pubmed_authors>Kim W</pubmed_authors><pubmed_authors>Gil JY</pubmed_authors><pubmed_authors>Han JM</pubmed_authors><pubmed_authors>Kim JH</pubmed_authors><pubmed_authors>Choi KH</pubmed_authors></additional><is_claimable>false</is_claimable><name>One-Year Risk of Bleeding in Patients on a Stable Warfarin Dose After Prosthetic Heart Valve Surgery.</name><description>&lt;h4>Purpose&lt;/h4>Anticoagulation therapy is required to prevent thromboembolic complications in patients with heart valve surgery (HVS). However, caution must be taken due to the risk of bleeding. This study aimed to identify bleeding risk factors in patients with stable warfarin therapy and develop a predictive tool for high-risk patients.&lt;h4>Methods&lt;/h4>This study is a nested case-control design using the Korean National Health Insurance Service-National Sample Cohort Data. We identified patients who underwent HVS and were prescribed warfarin within 1 week after the procedure. Of these, patients with the last two identical warfarin prescriptions within 6 months before the bleeding events were defined as the case group, while patients with no bleeding events within 6 months after HVS and t</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-06-01T06:21:07.422Z</modification><creation>2026-04-08T09:45:48.256Z</creation></dates><accession>S-EPMC12437997</accession><cross_references><pubmed>40955048</pubmed><doi>10.1002/pds.70209</doi></cross_references></HashMap>